Article

COVID-19: No strong local response of the conjunctival immune system

Author(s):

Symptoms in the eye may not be substantial in patients with COVID-19.

COVID-19: No strong local response of the conjunctival immune system

Ophthalmic symptoms may not constitute a substantial element in the clinical picture of novel COVID-19 infection, according to investigators.

Polish investigators, led by Anna Niedźwiedź, MD, from the Department of General Pathology, Pomeranian Medical University, Szczecin, Poland, reported that the SARS-CoV-2 virus does not cause a strong local response of the conjunctival immune system, meaning that symptoms in the eye may not be substantial in patients with COVID-19.1

The investigators conducted a study in which they assessed the presence and duration of ocular symptoms during early-phase COVID-19 infections to determine the local immune response on the ocular surface.

The study was based on concerns by clinicians that the SARS-CoV-2 virus was transmitted via the tears and conjunctival secretions. In addition, some patients had conjunctivitis as the first symptom of COVID-19, which the authors explained may indicate that the ocular route could be a probable transmission path of SARS-CoV-2 to the rest of the human body.

The main outcome among the 180 study patients compared with 160 healthy age-matched controls was the occurrence of ophthalmologic manifestations at hospital admission and during the previous 7 days before admission. The investigators measured the tear film concentrations of tumor necrosis factor-α, interleukin-1b, -2, -4, -5, -6, -8, -10, -12 p70, granulocyte-macrophage colony-stimulating factor, and interferon-gamma.

Among the patients, 13% and 24%, respectively, exhibited at least one ocular symptom at admission and symptoms within the 7 days before hospital admission, which was significant compared with controls(p < 0.001). The patients complained significantly more often about ocular tearing (p = 0.04) and pain (p = 0.01) than controls.

Multivariate analysis showed that COVID-19 was a significant independent factor associated with higher levels of vascular endothelial growth factor and interleukin-10 tear film concentrations (p = 0.047 and p < 0.001, respectively) and significantly lower levels of interleukin-1β, interleukin-8, and granulocyte-macrophage colony-stimulating factor (p < 0.001; p = 0.004; and p = 0.0, respectively).

Based on the results, the investigators, “SARS-CoV-2 does not attract a strong local response of the conjunctival immune system; therefore, ophthalmic symptoms may not constitute a substantial element in the clinical picture of novel COVID-19 infection.”

Reference
  1. Niedźwiedź A, Kawa M, Pius-Sadowska E, et al. Evaluating ocular symptoms and tear film cytokine profiles in symptomatic COVID-19 patients. J Clin Med. 2022;11:2647; https://doi.org/10.3390/jcm11092647

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
© 2025 MJH Life Sciences

All rights reserved.